Acura Pharmaceuticals (ACUR) 10-Q 14 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares shares in Thousands	6 Months Ended
	Jun. 30, 2018	Aug. 13, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	786,947
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		21,033,528

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets:
Cash and cash equivalents	$ 568	$ 2,220
Royalty receivable	94	71
Prepaid expenses and other current assets	154	275
Refundable deposits	100	0
Total current assets	916	2,566
Income tax receivable	135	135
Property, plant and equipment, net (Note 6)	641	679
Intangible asset, (net of accumulated amortization of $879 and $776) (Note 3)	1,121	1,224
Total assets	2,813	4,604
Liabilities:
Accounts payable	662	3
Accrued expenses (Note 7)	795	939
Accrued interest	767	700
Other current liabilities	19	41
Sales returns liability	254	254
Debt, (net of discounts) (Note 8)	1,505	2,694
Total current liabilities	4,002	4,631
Accrued interest	8	0
Notes payable – related party, (net of discounts)	1,429	0
Total liabilities	5,439	4,631
Commitments and contingencies (Note 15)
Stockholders' deficit:
Common stock - $.01 par value per share; 100,000 shares authorized, 21,034 and 20,796 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	210	208
Additional paid-in capital	380,299	380,145
Accumulated deficit	(383,135)	(380,380)
Total stockholders' deficit	(2,626)	(27)
Total liabilities and stockholders' deficit	$ 2,813	$ 4,604

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accumulated amortization, deferred finance costs	$ 879	$ 776
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	21,034	20,796
Common stock, shares outstanding	21,034	20,796

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
License fee revenue	$ 0	$ 0	$ 0	$ 2,500
Collaboration revenue	0	23	0	59
Royalty revenue	76	69	274	143
Product sales, net	0	0	0	107
Total revenues, net	76	92	274	2,809
Cost and expenses:
Cost of sales	0	0	0	128
Research and development	477	1,020	1,127	1,731
Selling, marketing, general and administrative	846	1,063	1,789	2,359
Total cost and expenses	1,323	2,083	2,916	4,218
Operating loss	(1,247)	(1,991)	(2,642)	(1,409)
Interest expense, net (Note 10)	(14)	(158)	(113)	(335)
Loss before income taxes	(1,261)	(2,149)	(2,755)	(1,744)
Provision for income taxes	0	0	0	0
Net loss	$ (1,261)	$ (2,149)	$ (2,755)	$ (1,744)
Loss per share:
Basic	$ (0.06)	$ (0.18)	$ (0.13)	$ (0.15)
Diluted	$ (0.06)	$ (0.18)	$ (0.13)	$ (0.15)
Weighted average shares outstanding:
Basic	21,101	11,966	21,068	11,938
Diluted	21,101	11,966	21,068	11,938

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT - 6 months ended Jun. 30, 2018 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ (27)	$ 208	$ 380,145	$ (380,380)
Balance (in shares) at Dec. 31, 2017		20,796
Net loss	(2,755)	$ 0	0	(2,755)
Non-cash share-based compensation	122	0	122	0
Net distribution of common stock pursuant to restricted stock unit award plan	34	$ 2	32	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		238
Balance at Jun. 30, 2018	$ (2,626)	$ 210	$ 380,299	$ (383,135)
Balance (in shares) at Jun. 30, 2018		21,034

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities:
Net loss	$ (2,755)	$ (1,744)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	38	47
Provision for sales returns	0	49
Non-cash share-based compensation	122	233
Capitalized debt discount	(74)	0
Amortization of debt discount and deferred debt issue costs	34	56
Amortization of intangible asset	103	103
Gain on disposal of machinery & equipment	0	(3)
Change in assets and liabilities:
Trade accounts receivable	0	23
Collaboration revenue receivable	0	78
Royalty receivable	(23)	0
Inventory	0	103
Prepaid expenses and other current assets	121	(294)
Refundable deposits	(100)	0
Accounts payable	659	505
Accrued expenses	(144)	(12)
Accrued interest	75	105
Other current liabilities	10	11
Sales returns liability	0	(49)
Net cash used in operating activities	(1,934)	(789)
Cash Flows from Investing Activities:
Proceeds from transfer of equipment to licensee	0	103
Proceeds from transfer of inventory to licensee	0	206
Net cash provided by investing activities	0	309
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	2	0
Proceeds from loan maturing February 2, 2020	1,500	0
Principal payments on loan maturing December 1, 2018	(1,220)	(1,122)
Net cash provided by (used in) financing activities	282	(1,122)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(1,652)	(1,602)
Cash, cash equivalents, and restricted cash at beginning of period	2,220	5,181
Cash, cash equivalents, and restricted cash at end of period	568	3,579
Supplemental disclosure of cash flow information:
Cash interest payments on loan maturing December 1, 2018	78	176
Cash	568	1,077
Cash equivalents	0	2
Restricted cash equivalents	0	2,500
Total cash, cash equivalents and restricted cash show in the consolidated statements of cash flows	$ 568	$ 5,181

CONSOLIDATED STATEMENTS OF CAS7

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Payments of Debt Issuance Costs	$ 74	$ 0	$ 74	$ 0
Proceeds from Issuance of Long-term Debt			$ 1,500	$ 0

OPERATIONS AND BASIS OF PRESENT

OPERATIONS AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2018
Description Of Operation And Summary Of Significant Accounting Policies Disclosure [Abstract]
OPERATIONS AND BASIS OF PRESENTATION	NOTE 1 – OPERATIONS AND BASIS OF PRESENTATION Principal Operations Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to address methods of product tampering associated with opioid abuse by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine. · Our Limitx Technology is in development with the immediate-release hydrocodone bitartrate and acetaminophen as a lead Limitx product candidate due to its larger market size than our prior lead product and its known prevalence of oral excessive tablet abuse. · Our Aversion Technology has been licensed to Egalet Corporation for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. (see Note 3). · Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC our Impede Technology in the United States and Canada to commercialize our Nexafed products. (see Note 3). Basis of Presentation and Substantial Doubt in Going Concern The accompanying unaudited consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all disclosures required by generally accepted accounting principles. Reference should be made to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of the Company, all normal recurring adjustments have been made that are necessary to present fairly the results of operations for the interim periods. Operating results for the six month period ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of June 30, 2018, we had cash and refundable deposits of $0.7 million, working capital deficit of $3.1 million and an accumulated deficit of $383.1 million. As of August 13, 2018 we had cash and refundable deposits of $0.2 million. We had a loss from operations of $2.6 million and a net loss of $2.8 million for the six months ended June 30, 2018. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We had a loss from operations of $5.2 million and a net loss of $5.7 million for the year ended December 31, 2017. We anticipate operating losses to continue for the foreseeable future. We have a term loan with Oxford Finance LLC (“Oxford” or the “Lender”) and as of June 30, 2018 and August 13, 2018, the outstanding principal balance is $1.5 million and $1.0 million, respectively. The $795 thousand balloon interest payment is due to Oxford on December 1, 2018. Our term loan agreement with Oxford contains customary affirmative and negative covenants. One such covenant is that the Company must submit on an annual basis to Oxford, within 120 days after the end of its fiscal year, audited financial statements, together with an unqualified audit opinion from an independent registered public accounting firm, or the Unqualified Audit Opinion Covenant. Per the term loan agreement an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business (the “going concern opinion”) is deemed to violate the Unqualified Audit Opinion Covenant. Failure to comply with the Unqualified Audit Opinion Covenant is a breach of the term loan agreement and unless such covenant or breach is waived, Oxford would have the option of accelerating the debt under the term loan agreement and initiating enforcement collection actions, foreclosing on collateral (which includes most assets of the Company) and, among other things, preventing the Company from using any funds in its bank or securities accounts. On March 16, 2017, we and Oxford entered into a third amendment to the loan agreement, or the Third Amendment. Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. During the second quarter of 2018, we borrowed a total of $1.5 million from John Schutte, a principal of MainPointe and our largest shareholder. In conjunction with such loans, we entered into of a fourth amendment to our term loan agreement with Oxford, pursuant to which Oxford granted a similar waiver of compliance with the Unqualified Audit Opinion Covenant for our 2017 financial statements and extended the period in which we could deliver financial statements for 2017 to 160 days after year’s end (instead of 120 days). (see Notes 9 and 15). On June 7, 2018, we filed our 2017 financial statements as part of our annual report on Form 10-K. We borrowed another $400 thousand from John Schutte on August 2, 2018 and our total borrowing to date with John Schutte is $1.9 million. With the net proceeds to the Company resulting from the loans from Mr. Schutte, we expect our cash will only be sufficient to fund operations into late August 2018. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. We must seek sources to raise additional financing and seek to enter into license or collaboration agreements with third parties relating to our technologies. The Company is exploring a variety of capital raising and other transactions to provide additional funding to continue operations. These include potential private offerings of common stock to accredited and/or institutional investors and licensing transactions with pharmaceutical company partners for our proprietary technologies, including Limitx. We are actively seeking a licensing partner for our Limitx technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx technology, similar to the Egalet Agreement. We are also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company continues to evaluate the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in completing any one or more of such transactions on acceptable terms, if at all, or if completed, that such transactions will provide payments to the Company sufficient to fund continued operations. In the absence of the Company’s completion of one or more of such transactions, there will be substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued, and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS New accounting standards which have been adopted on or before June 30, 2018 Revenue from Contracts with Customers The Company adopted Accounting Standards Codification Topic 606—Revenue from Contracts with Customers, or Topic 606, on January 1, 2018, resulting in a change to its accounting policy for revenue recognition. The Company used the modified retrospective method and the cumulative effect of initially applying Topic 606 would be recognized as an adjustment to the opening accumulated deficit at January 1, 2018. Accordingly, comparative information has not been adjusted and continues to be reported under the previous accounting standards. Refer to Note 4 for additional information. Scope of Modification Accounting, Stock Based Compensation In May 2017, the FASB issued ASU No. 2017-09 which provides guidance as to how an entity should apply modified accounting in Topic 718 when changing the terms and conditions of its share-based payment awards. The guidance clarifies that modification accounting will be applied if the value, vesting conditions or classification of the award changes. The ASU is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017 but early adoption is permitted. The Company adopted this new standard on January 1, 2018 which did not have a material impact on the Company’s financial statements. Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU 2016-15 which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company adopted this new standard on January 1, 2018 which did not have a material impact on the Company’s financial statements. Intra-Entity Transfers of Assets Other than Inventory In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory New accounting standards which have not been adopted on or before June 30, 2018 Leases In February 2016, the FASB issued ASU 2016-02, Leases, which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018 but early adoption is permitted. The new standard must be presented using the modified retrospective transition method existing at or entered into after the beginning of the earliest comparative period presented in the financial statements, but it does not require transition accounting for leases that expire prior to the date of initial application. Upon adoption, operating leases will be reported on the balance sheet as a gross-up of assets and liabilities. The Company is currently evaluating the impact that the standard will have on the financial statements and related footnote disclosures.

LICENSE AND COLLABORATION AGREE

LICENSE AND COLLABORATION AGREEMENTS	6 Months Ended
	Jun. 30, 2018
License and Collaboration Agreements [Abstract]
LICENSE AND COLLABORATION AGREEMENTS	NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS The Company’s revenues are comprised of amounts earned under its license and collaboration agreements, royalties, and until March 2017 did previously include the Nexafed products’ net product sales. Revenue recognition occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services based on a short-term credit arrangement. Egalet Agreement covering Oxaydo In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded amortization expense of $103 thousand in each of the six month periods ending June 30, 2018 and 2017. Annual amortization of the patent for its remaining life through 2021 is expected to approximate $208 thousand each year. In January 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, or collectively Egalet, entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. Egalet paid us a $5.0 million license fee upon signing of the Egalet Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor. The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period. MainPointe Agreement covering Nexafed products In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country. MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. KemPharm Agreement Covering Certain Opioid Prodrugs In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free. The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm. Terminated Bayer Agreement Covering Methamphetamine Resistant Pseudoephedrine-containing Product In June 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine–containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. In June 2017, we received Bayer’s notice of termination of the Bayer Agreement pursuant to its convenience termination right exercised prior to the Company’s completion of its product development obligations under the Bayer Agreement. We have received reimbursement of certain of our development costs under the Bayer Agreement. Following Bayer’s termination of the Bayer Agreement the Bayer Licensed Product is now subject to MainPointe’s option rights under the MainPointe Agreement.

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	NOTE 4 – REVENUE FROM CONTRACTS WITH CUSTOMERS Adoption of ASC Topic 606, Revenue from Contracts with Customers The Company adopted ASC Topic 606 on January 1, 2018 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. While the timing of future revenues under ASC Topic 606 may differ from the Company’s historical accounting practices under ASC Topic 605, the cumulative effect recorded through the Consolidated Statement of Stockholder’s Deficit was zero because there was no change in timing or measurement of revenues for open contracts at January 1, 2018. Under ASC 606, revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at June 30, 2018. The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract. Net Product Sales Prior to the licensing the Nexafed products to MainPointe in March 2017, we sold our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products were sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products had an initial shelf life of twenty-four months from the date of manufacture, which shelf life had been extended to thirty-six months for Nexafed product supplied to us during 2016 from one of the Company’s contract manufacturers. We recognized revenue from our Nexafed products sales when the price was fixed and determinable at the date of sale, title and risk of ownership were transferred to the customer, and returns could be reasonably estimated, which generally occurred at the time of product shipment. ASC 606 did not change the practice under which the Company previously recognized the product revenue from sales of the Nexafed products, which was at the time the product was shipped to a customer. As a result of the Company’s license agreement with MainPointe completed in March 2017, the Company no longer sold the Nexafed products. There was a $0 effect to the recognition of revenue for Nexafed product sales under the adoption of ASC 606. Sales-based Milestones and Royalty Revenues The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Egalet and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter. License and Collaboration Agreement Revenues The achievement of milestones under the Company’s license and collaboration agreements will be recorded during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled, which may result in later recognition as compared to the previous accounting standards. Disaggregation of Total Revenues The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Egalet. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S. Royalty revenues by licensee are summarized below: Three months Ended June 30, 2018 Six months Ended June 30, 2018 (in thousands) Egalet $ 70 $ 260 MainPointe 6 14 Royalty revenues $ 76 $ 274 Contract Balance and Performance Obligations The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2018 or December 31, 2017 was $0.00. Contract assets may be reported in future periods under prepaid expenses or other current assets on the balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the balance sheet.

RESEARCH AND DEVELOPMENT ACTIVI

RESEARCH AND DEVELOPMENT ACTIVITIES	6 Months Ended
	Jun. 30, 2018
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT ACTIVITIES	NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at June 30, 2018 or December 31, 2017.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 6 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at June 30, 2018 and December 31, 2017 are summarized as follows: June 30, December 31, 2018 2017 (in thousands) Building and improvements $ 1,273 $ 1,273 Scientific equipment 598 598 Computer hardware and software 107 107 Machinery and equipment 275 275 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 Total 2,512 2,512 Less: accumulated depreciation (1,871 ) (1,833 ) Net property, plant and equipment $ 641 $ 679 We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 7 - ACCRUED EXPENSES Accrued expenses at June 30, 2018 and December 31, 2017 are summarized as follows: June 30, December 31, 2018 2017 (in thousands) Cost sharing expenses under license agreement $ 412 $ 328 Other fees and services 34 36 Payroll, payroll taxes and benefits 77 70 Professional services 127 149 Clinical, non-clinical and regulatory services 118 326 Property taxes 13 16 Franchise taxes 14 14 Total $ 795 $ 939

DEBT

DEBT	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
DEBT	NOTE 8 – DEBT Loan due December 1, 2018 In December 2013, we entered into a Loan and Security Agreement (the “Oxford Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the initial Oxford Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Pursuant to the Oxford Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Oxford Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020. In January 2015, we and Oxford entered into an amendment to the Oxford Loan Agreement. Pursuant to the amendment, (i) the exercise price of the warrants was lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the warrant modification, (ii) we agreed to maintain $2.5 million cash reserves until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product. In October 2016, we and Oxford entered into a second amendment to the Oxford Loan Agreement (the “Second Amendment”). Pursuant to the Second Amendment, (i) the requirement that we maintain a $2.5 million cash balance reserve until such time as $5.0 million in principal was repaid under the Term Loan has been modified so that the $2.5 million cash balance reserve remains in place until we raise an additional $6.0 million (excluding payments received under the KemPharm Agreement) through the issuance of equity securities and from upfront payments under license, joint venture, collaboration or other partnering transactions, provided that at least $3.0 million of such amount must be raised through the issuance and sale of our equity securities, and (ii) the Lender consented to the terms of our Agreement with KemPharm. In July 2017, the Company completed a private placement of its equity units to an investor, each unit consisting of one share of common stock and a warrant to purchase one-fifth of a share of common stock. The net proceeds to the Company from the private offering was approximately $4.0 million. Giving effect to the $2.5 million upfront payment received from MainPointe pursuant to the MainPointe Agreement and the approximate $4.0 million in net proceeds from the July 2017 private offering, the Company has satisfied the condition in the Second Amendment to the Oxford Loan Agreement to waive the $2.5 million cash reserve requirement. In March 2017, we and Oxford entered into a third amendment to the Oxford Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. Under the Oxford Loan Agreement, an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business is deemed to violate the Unqualified Audit Opinion Covenant. During the second quarter 2018, in connection with $1.5 million loans extended to us by John Schutte, we and Oxford entered into a fourth amendment to the Oxford Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s opinion with a going concern explanatory paragraph for our 2017 financial statements and allowed us to deliver financial statements up to 160 days after year end, instead of 120 days after year end. On June 7, 2018 we filed our 2017 financial statements. The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1% of the principal prepaid. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We are accruing additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate. As of June 30, 2018 and December 31, 2017, we have accumulated and accrued $767 thousand and $700 thousand of additional interest, respectively. The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Oxford Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%. The Oxford Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Oxford Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non−payment defaults, covenant defaults (including breach of the Unqualified Audit Opinion Covenant), a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults. Loan due January 2, 2020 During the second quarter 2018, we borrowed $1.5 million from John Schutte, a related-party, and issued two promissory notes (the Schutte Notes), in that aggregate principal amount to him. The Schutte Notes bear interest at prime plus 2.0%, and mature on January 2, 2020, at which time all principal and interest is due, and are unsecured until all obligations to Oxford are satisfied at which time we are required to grant a security interest to Mr. Schutte in all of our assets. Because we believe the promissory note’s rate of interest is below current market rates for us, we imputed interest on the below market rate element of the loan using the 10.16% interest rate under the Oxford Loan Agreement which amounted to $74 thousand. We recorded the $74 thousand as a benefit to interest income in the three month period ended June 30, 2018 with a corresponding like amount as debt discount against the principal amount of the loan. The debt discount will be amortized to interest expense over the term on the loans. The events of default under the Schutte Notes are limited to bankruptcy defaults and failure to pay interest and principal when due on January 2, 2020. In addition, Mr. Schutte and Oxford entered into a subordination agreement, approved by us and our subsidiary, pursuant to which Mr. Schutte subordinated the Schutte Notes to our obligations to Oxford under the Oxford Loan Agreement. The Schutte Notes may be prepaid at any time in whole or in part, however while Oxford’s loan is outstanding such prepayment will require Oxford’s consent. Our debt at June 30, 2018 is summarized below (in thousands): Current Long-term Total Loan Due December 1, 2018 Balance at Jan. 1, 2018 $ 2,740 $ - $ 2,740 Principal payments (1,220 ) - (1,220 ) Balance at Jun. 30, 2018 $ 1,520 $ - $ 1,520 Loan Due January 2, 2020 Balance at Jan. 1, 2018 $ - $ - $ - Borrowings - 1,500 1,500 Balance at Jun. 30, 2018 $ - $ 1,500 $ 1,500 Debt Discount Current Long-term Total Balance at Jan. 1, 2018 $ (32 ) $ - $ (32 ) Additions - (74 ) (74 ) Amortization expense 21 3 24 Balance at Jun. 30, 2018 $ (11 ) $ (71 ) $ (82 ) Deferred Debt Issuance Costs Current Long-term Total Balance at Jan. 1, 2018 $ (14 ) $ - $ (14 ) Amortization expense 10 - 10 Balance at Jun. 30, 2018 $ (4 ) $ - $ (4 ) Debt, net at Jun. 30, 2018 $ 1,505 $ 1,429 $ 2,934 Our debt interest expense for the three and six months ended June 30, 2018 and 2017 consisted of the following (in thousands): Three months Ended June 30, Six months Ended June 30, Interest expense: 2018 2017 2018 2017 Term loan – due December 1, 2018 $ 63 $ 133 $ 145 $ 281 Term loans – due January 2, 2020 8 - 8 - Debt discount 13 17 24 37 Debt issue costs 4 9 10 19 Total interest expense $ 88 $ 159 $ 187 $ 337 Less: imputed interest income on related party loan (74 ) - (74 ) - Less: interest income - (1 ) - (2 ) Total interest expense, net $ 14 $ 158 $ 113 $ 335

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS In July 2017, we completed a $4.0 million private placement with John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units ) of the Company, at a price of $0.4488 per Unit (the “Transaction Each Unit consists of one share of Common Stock and a Warrant to purchase one fifth (0.2) of a share of Common Stock. The issue price of the Units was equal to 85% of the average last sale price of our Common Stock for the five trading days prior to completion of the Transaction. The Warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s Common Stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933. Investor is a principal of MainPointe, a Kentucky limited liability company. In March 2017, we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company will receive a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported revenue for the six month period ending June 30, 2018 is $8 thousand of royalty revenue from MainPointe. (See Note 3). As part of the closing of the Transaction, the Company, Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our Common Stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Galen has not designated a director and lost that right in December 2017 when it disposed of its shares. Investor has not designated a director as of the date of filing of this Report. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. During the second quarter of 2018, we borrowed $1.5 million from John Schutte and issued two promissory notes in that aggregate principal amount to him. See Note 8 for a discussion of this transaction.

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	6 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
COMMON STOCK WARRANTS	NOTE 10 - COMMON STOCK WARRANTS We had no activity in our warrants for either the six months ended June 30, 2018 or 2017. Our warrants consisted of the following (in thousands except price data): June 30, 2018 2017 Number WAvg Exercise Price Number WAvg Exercise Price Outstanding, Jan. 1, 1,842 $ 0.59 60 $ 2.52 Issued - - - - Exercised - - - - Expired -- - - Modification -- - - Outstanding, Jun. 30, 1,842 $ 0.59 60 $ 2.52 In connection with the issuance of the $10.0 million secured promissory notes in December 2013, we issued common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. See Note 8 for a discussion of the reduction of the exercise price of these warrants to $2.52 per share. These warrants contain a cashless exercise feature. As part of our July 2017 private placement transaction with John Schutte, we issued warrants to purchase 1,782,531 shares of our common stock. The Warrants are immediately exercisable at a price of $0.528 per share and expire five years after issuance (see Note 9). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2018
Equity, Fair Value Disclosure [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our debt. The carrying amounts of these financial instruments, other than our long-term debt, are representative of their respective fair values due to their relatively short maturities.

SHARE-BASED COMPENSATION EXPENS

SHARE-BASED COMPENSATION EXPENSE	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION EXPENSE	NOTE 12 - SHARE-BASED COMPENSATION EXPENSE Share-based Compensation We have four share-based compensation plans covering stock options and RSUs for our employees and directors. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following: Three months Ended June 30, Six months Ended June 30, 2018 2017 2018 2017 (in thousands) Research and development costs: Stock options $ 11 $ 34 $ 24 $ 68 Restricted stock units 7 - 14 - Subtotal $ 18 $ 34 $ 38 $ 68 General and administrative costs: Stock options $ 19 $ 53 $ 53 $ 106 Restricted stock units 29 42 51 84 Subtotal $ 48 $ 95 $ 104 $ 190 Total $ 66 $ 129 $ 142 $ 258 Included in the table’s reported totals for general and administrative costs is share-based compensation expense from the marked-to-market accounting of a portion of the RSUs granted to our directors is approximately $7 thousand and $13 thousand for the three month periods ended June 30, 2018 and 2017, respectively and approximately $20 thousand and $25 thousand for the six month periods ended June 30, 2018 and 2017, respectively. Stock Option Award Plans We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2018 and 2017 is shown below (in thousands except price data): Six months Ended June 30, 2018 2017 Number of Options (000’s) Weighted Average Exercise Price Number of Options (000’s) Weighted Average Exercise Price Outstanding, Jan. 1, 1,494 $ 12.33 1,397 $ 13.57 Granted - - - - Exercised - - (1 ) (0.92 ) Forfeited or expired (145 ) (46.39 ) - - Outstanding, Jun. 30, 1,349 $ 8.68 1,396 $ 13.58 Options exercisable 1,129 $ 10.26 1,190 $ 15.71 The following table summarizes information about nonvested stock options outstanding at June 30, 2018 (in thousands except price data): Number of Weighted Outstanding, Jan. 1, 2018 270 $ 0.46 Granted - - Vested (46 ) 0.77 Forfeited (4 ) 0.41 Outstanding, Jun. 30, 2018 220 $ 0.39 We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. The intrinsic value of the option awards which were vested and outstanding at each of June 30, 2018 and 2017 was $0 thousand. The total remaining unrecognized compensation cost on unvested option awards outstanding at June 30, 2018 was $34 thousand, and is expected to be recognized in operating expense in varying amounts over the 5 months remaining in the requisite service period. Restricted Stock Unit Award Plans We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. Our non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The portion of the RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet as they vest and being marked-to-market each reporting period until they are distributed. The liability was $19 thousand and $41 thousand at June 30, 2018 and December 31, 2017, respectively. The compensation cost to be incurred on a granted RSU without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense and recorded to additional paid-in capital over the vesting period of the RSU award. The total remaining unrecognized compensation cost on unvested RSU awards outstanding at June 30, 2018 was $27 thousand, and is expected to be recognized in operating expense over the 6 months remaining in the requisite service period. A summary of the award activity under the RSU Plans as of June 30, 2018 and 2017, and for each of the six month period then ended consisted of the following: Six months Ended June 30, 2018 2017 (in thousands) Number of RSUs Number of Vested RSUs Number of RSUs Number of Vested RSUs Outstanding, Jan. 1 462 262 91 91 Granted 267 - 238 - Distributed (262 ) (262 ) (67 ) (67 ) Vested - 133 - 118 Forfeited or expired (8 ) - - - Outstanding, Jun. 30 459 133 262 142 2017 Restricted Stock Unit Award Plan Our 2017 RSU Plan was approved by shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. As of June 30, 2018, approximately 1.0 million shares are available for award under the 2017 RSU Plan. Information about the awards under the 2017 RSU Plan is as follows: · In December 2017, we awarded 200 thousand RSUs to our employees. Such RSU awards will vest 100% after one full year of service. Distributions of the vested RSU awards to the employees will be made in three equal installments on the first business day of each of January 2020, 2021, and 2022 or earlier upon a qualifying change of control. · In January 2018, we awarded approximately 67 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2018. Distributions of stock under the January 2018 award will be distributed on January 2, 2019, the first business day of the year after vesting. 2014 Restricted Stock Unit Award Plan Our 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of June 30, 2018, approximately 3 thousand shares are available for award under the 2014 RSU Plan. Information about the awards under the 2014 RSU Plan during 2017 and 2018 is as follows: · In January 2017, we awarded approximately 60 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2017. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $41 thousand at December 31, 2017. Distributions of stock under this award was distributed on January 2, 2018. Information about the distribution of shares under the 2014 RSU Plan is as follows: · In January 2017, 1 thousand RSUs from the May 2014 award and 66 thousand RSUs from the January 2016 award were distributed. There were 1 thousand RSUs from the May 1 2014 award and 22 thousand RSUs from the January 2016 award which remained deferred until a future distribution date, which occurred on January 1, 2018. Of the 67 thousand RSUs distributed, 49 thousand RSUs were distributed in common stock and 18 thousand RSUs were settled in cash. · In January 2018, all outstanding 262 thousand RSUs from the 2014 RSU Plan were distributed. Of the approximately 262 thousand RSUs distributed, 238 thousand RSUs were distributed in common stock and 24 thousand RSUs were settled in cash.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017 and requiring adjustment to 2017 deferred taxes. Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $169 million gross Federal NOLs at June 30, 2018 (of which approximately $168 million were generated prior to 2018). Because we believe the ability for us to use the Federal NOLs generated prior to January 1, 2018 to offset future taxable income is severely limited, as prescribed under Internal Revenue Code (“IRC”) Section 382, we have estimated and recorded an amount for the likely limitation to our deferred tax asset. The amount we recorded thereby reduced the aggregate estimated benefit of the Federal NOLs generated prior to January 1, 2018 to approximately $1.0 million. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 to offset future taxable income is less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before January 1, 2018 and Federal NOLs generated after December 31, 2017 can be carried forward indefinitely. Future common stock transactions may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both June 30, 2018 and December 31, 2017, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NOTE 14 – NET LOSS PER SHARE Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 12). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2018 as the Company reported a net loss for the six month period, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common shares outstanding diluted computation is not impacted during any period where the exercise price of a stock option or common stock warrant is greater than the average market price. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data): Three months Ended June 30, Six months Ended June 30, 2018 2017 2018 2017 EPS – basic and diluted Numerator: net loss $ (1,261 ) $ (2,149 ) $ (2,755 ) $ (1,744 ) Denominator (weighted): Common shares 21,034 11,883 21,034 11,884 Vested RSUs 67 83 34 54 Basic and diluted weighted average shares outstanding 21,101 11,966 21,068 11,938 EPS – basic and diluted $ (0.06 ) $ (0.18 ) $ (0.13 ) $ (0.15 ) Excluded securities (non-weighted): Common shares issuable: Stock options – vested and nonvested 1,349 1,396 1,349 1,396 RSUs - nonvested 326 120 326 120 Common stock purchase warrants 1,842 60 1,842 60 Total excluded common shares 3,517 1,576 3,517 1,576

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES Reglan ® /Metoclopramide Litigation Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing In Pennsylvania, the trial court proceedings were stayed on January 12, 2017. On June 15, 2017, the Court entered an Order approving a stipulation which dismisses nearly all of the individual cases against us based upon lack of product identification without prejudice and provides for these cases to be dismissed finally, with prejudice, as of June 15, 2018. We expect that the Court will finally dismiss the Pennsylvania-based litigation against us with prejudice in 2018. Legal fees related to this matter are currently covered by our insurance carrier. In California, on May 24, 2016, the Court entered an Order approving a stipulation which stays the individual cases against us and provides for an agreed upon dismissal protocol for all cases where is a lack of product identification. On January 13, 2017, the Court also entered a general stay of this entire litigation. To date, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by us. Therefore, we expect that the lawsuits filed against us will be dismissed voluntarily with prejudice later in 2018. Legal fees related to this matter are currently covered by our insurance carrier. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of June 30, 2018 and we are presently unable to determine if any potential loss would be covered by our insurance carrier. DES Litigation On April 12, 2018, an action was commenced against the Company and over twenty-five other pharmaceutical manufacturers in New York State Supreme Court, New York County, captioned Cotto et al. v. Abbott Laboratories, Inc., et al Purdue Pharma Settlement In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “ 007 patent”). In April 2016, Purdue commenced a second patent infringement lawsuit against us and Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s newly issued U.S. Patent No. 9,308,171 (the “171 Patent”). The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Partes Review (the “IPR Review”) with the U.S. Patent and Trademark Office (“USPTO”) seeking to invalidate Purdue’s 007 Patent. On May 20, 2016, Purdue on behalf of themselves and certain affiliates, Egalet Corporation, on behalf of itself and its affiliates and we, on behalf of ourselves and our affiliates entered into a settlement agreement (the “Settlement Agreement”) to settle the Actions and the IPR Review. Under the Settlement Agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made under the Settlement Agreement. The Settlement Agreement also provides that Purdue will not, in the future, assert certain Purdue U.S. patents, including the 007 Patent, the 171 Patent and related technologies (the “Purdue Patents”) against any Acura Settlement Product or Egalet Settlement Product (except generally in an action or interference by Acura or Egalet challenging a Purdue Patent). Acura Settlement Products and Egalet Settlement Products are certain immediate-release and extended-release products, including Oxaydo. In addition, the Settlement Agreement provides that Purdue will not challenge, with certain exceptions, the Acura/Egalet Patents with respect to the Purdue Settlement Products (as defined below) and that Purdue provides Acura and/or Egalet certain waivers of non-patent marketing exclusivity with respect to Purdue Settlement Products. The Settlement Agreement also provides that Acura and Egalet will not, in the future, assert certain Acura and/or Egalet U.S. patents (the “Acura/Egalet Patents”), including Acura’s Aversion® Technology patents, against any Purdue Settlement Products (except generally in an action or interference by Purdue challenging an Acura/Egalet Patent). Purdue Settlement Products are certain immediate-release and extended-release products. In addition, the Settlement Agreement provides that Acura and Egalet will not challenge, with certain exceptions, the Purdue Patents with respect to the Acura Settlement Products and Egalet Settlement Products and that Acura and Egalet provide Purdue certain waivers of non-patent marketing exclusivity with respect to the Acura Settlement Products and Egalet Settlement Products. In addition, Purdue has certain rights to negotiate to exclusively distribute an authorized generic version of certain Egalet Settlement Products, including, in some circumstances, Oxaydo® and other products using Acura’s Aversion® Technology if licensed to Egalet. The Settlement Agreement specifically excludes our patents related to our Impede® and Limitx™ technologies from the scope of the Acura/Egalet Patents under the Settlement Agreement. In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue Pharma relating to the December 2014 agreement. Egalet Agreement covering Oxaydo On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the expenses and we will pay for the remaining fees and expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. At June 30, 2018 we have accrued approximately $412 thousand of these potential cost sharing reimbursable expenses under the Egalet Agreement.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 16 – SUBSEQUENT EVENT Loan Due January 2, 2020 On August 2, 2018 we borrowed $0.4 million from John Schutte and issued a promissory note in that aggregate principal amount to him. To date we have borrowed $1.9 million from him (the Schutte Notes). The Schutte Notes bear interest at prime plus 2.0%, and mature on January 2, 2020, at which time all principal and interest is due, and are unsecured until all obligations to Oxford are satisfied at which time we are required to grant a security interest to Mr. Schutte in all of our assets. Events of default under the Schutte Notes are limited to bankruptcy defaults and failure to pay interest and principal when due on January 2, 2020. During the second quarter 2018, Mr. Schutte and Oxford entered into a subordination agreement, approved by us and our subsidiary, pursuant to which Mr. Schutte subordinated the Schutte Notes to our obligations to Oxford under the Oxford Loan Agreement. The Schutte Notes may be prepaid at any time in whole or in part, however while Oxford’s loan is outstanding such prepayment will require Oxford’s consent. Facility Lease The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately $2 thousand per month.

REVENUE FROM CONTRACTS WITH C24

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Egalet. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S. Royalty revenues by licensee are summarized below: Three months Ended June 30, 2018 Six months Ended June 30, 2018 (in thousands) Egalet $ 70 $ 260 MainPointe 6 14 Royalty revenues $ 76 $ 274

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	Property, plant and equipment at June 30, 2018 and December 31, 2017 are summarized as follows: June 30, December 31, 2018 2017 (in thousands) Building and improvements $ 1,273 $ 1,273 Scientific equipment 598 598 Computer hardware and software 107 107 Machinery and equipment 275 275 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 Total 2,512 2,512 Less: accumulated depreciation (1,871 ) (1,833 ) Net property, plant and equipment $ 641 $ 679

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Accurued Expenses	Accrued expenses at June 30, 2018 and December 31, 2017 are summarized as follows: June 30, December 31, 2018 2017 (in thousands) Cost sharing expenses under license agreement $ 412 $ 328 Other fees and services 34 36 Payroll, payroll taxes and benefits 77 70 Professional services 127 149 Clinical, non-clinical and regulatory services 118 326 Property taxes 13 16 Franchise taxes 14 14 Total $ 795 $ 939

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Debt	Our debt at June 30, 2018 is summarized below (in thousands): Current Long-term Total Loan Due December 1, 2018 Balance at Jan. 1, 2018 $ 2,740 $ - $ 2,740 Principal payments (1,220 ) - (1,220 ) Balance at Jun. 30, 2018 $ 1,520 $ - $ 1,520 Loan Due January 2, 2020 Balance at Jan. 1, 2018 $ - $ - $ - Borrowings - 1,500 1,500 Balance at Jun. 30, 2018 $ - $ 1,500 $ 1,500 Debt Discount Current Long-term Total Balance at Jan. 1, 2018 $ (32 ) $ - $ (32 ) Additions - (74 ) (74 ) Amortization expense 21 3 24 Balance at Jun. 30, 2018 $ (11 ) $ (71 ) $ (82 ) Deferred Debt Issuance Costs Current Long-term Total Balance at Jan. 1, 2018 $ (14 ) $ - $ (14 ) Amortization expense 10 - 10 Balance at Jun. 30, 2018 $ (4 ) $ - $ (4 ) Debt, net at Jun. 30, 2018 $ 1,505 $ 1,429 $ 2,934
Schedule of Interest Expense	Our debt interest expense for the three and six months ended June 30, 2018 and 2017 consisted of the following (in thousands): Three months Ended June 30, Six months Ended June 30, Interest expense: 2018 2017 2018 2017 Term loan – due December 1, 2018 $ 63 $ 133 $ 145 $ 281 Term loans – due January 2, 2020 8 - 8 - Debt discount 13 17 24 37 Debt issue costs 4 9 10 19 Total interest expense $ 88 $ 159 $ 187 $ 337 Less: imputed interest income on related party loan (74 ) - (74 ) - Less: interest income - (1 ) - (2 ) Total interest expense, net $ 14 $ 158 $ 113 $ 335

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule Of Common Stock Warrant Activity	We had no activity in our warrants for either the six months ended June 30, 2018 or 2017. Our warrants consisted of the following (in thousands except price data): June 30, 2018 2017 Number WAvg Exercise Price Number WAvg Exercise Price Outstanding, Jan. 1, 1,842 $ 0.59 60 $ 2.52 Issued - - - - Exercised - - - - Expired -- - - Modification -- - - Outstanding, Jun. 30, 1,842 $ 0.59 60 $ 2.52

SHARE-BASED COMPENSATION EXPE29

SHARE-BASED COMPENSATION EXPENSE (Tables)	6 Months Ended
	Jun. 30, 2018
Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following: Three months Ended June 30, Six months Ended June 30, 2018 2017 2018 2017 (in thousands) Research and development costs: Stock options $ 11 $ 34 $ 24 $ 68 Restricted stock units 7 - 14 - Subtotal $ 18 $ 34 $ 38 $ 68 General and administrative costs: Stock options $ 19 $ 53 $ 53 $ 106 Restricted stock units 29 42 51 84 Subtotal $ 48 $ 95 $ 104 $ 190 Total $ 66 $ 129 $ 142 $ 258
Schedule of Share-based Compensation, Stock Options, Activity	A summary of our stock option plan activity during the six month periods ending June 30, 2018 and 2017 is shown below (in thousands except price data): Six months Ended June 30, 2018 2017 Number of Options (000’s) Weighted Average Exercise Price Number of Options (000’s) Weighted Average Exercise Price Outstanding, Jan. 1, 1,494 $ 12.33 1,397 $ 13.57 Granted - - - - Exercised - - (1 ) (0.92 ) Forfeited or expired (145 ) (46.39 ) - - Outstanding, Jun. 30, 1,349 $ 8.68 1,396 $ 13.58 Options exercisable 1,129 $ 10.26 1,190 $ 15.71
Schedule of Nonvested Share Activity	The following table summarizes information about nonvested stock options outstanding at June 30, 2018 (in thousands except price data): Number of Weighted Outstanding, Jan. 1, 2018 270 $ 0.46 Granted - - Vested (46 ) 0.77 Forfeited (4 ) 0.41 Outstanding, Jun. 30, 2018 220 $ 0.39
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of the award activity under the RSU Plans as of June 30, 2018 and 2017, and for each of the six month period then ended consisted of the following: Six months Ended June 30, 2018 2017 (in thousands) Number of RSUs Number of Vested RSUs Number of RSUs Number of Vested RSUs Outstanding, Jan. 1 462 262 91 91 Granted 267 - 238 - Distributed (262 ) (262 ) (67 ) (67 ) Vested - 133 - 118 Forfeited or expired (8 ) - - - Outstanding, Jun. 30 459 133 262 142

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data): Three months Ended June 30, Six months Ended June 30, 2018 2017 2018 2017 EPS – basic and diluted Numerator: net loss $ (1,261 ) $ (2,149 ) $ (2,755 ) $ (1,744 ) Denominator (weighted): Common shares 21,034 11,883 21,034 11,884 Vested RSUs 67 83 34 54 Basic and diluted weighted average shares outstanding 21,101 11,966 21,068 11,938 EPS – basic and diluted $ (0.06 ) $ (0.18 ) $ (0.13 ) $ (0.15 ) Excluded securities (non-weighted): Common shares issuable: Stock options – vested and nonvested 1,349 1,396 1,349 1,396 RSUs - nonvested 326 120 326 120 Common stock purchase warrants 1,842 60 1,842 60 Total excluded common shares 3,517 1,576 3,517 1,576

OPERATIONS AND BASIS OF PRESE31

OPERATIONS AND BASIS OF PRESENTATION - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 02, 2018	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Aug. 13, 2018
Working Capital Deficit		$ 3,100			$ 3,100
Retained Earnings (Accumulated Deficit)		(383,135)			(383,135)		$ (380,380)
Operating Income (Loss)		(1,247)		$ (1,991)	(2,642)	$ (1,409)	5,200
Net Income (Loss) Attributable to Parent, Total		1,261		$ 2,149	2,755	1,744
Proceeds from Issuance of Long-term Debt					1,500	$ 0
Cash, Cash Equivalents, and Refundable Deposits		700			700
Long-term Debt		2,934			2,934
First Revenue Event Does Not Occurs [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid		795			795
Loan Agreement With Oxford [Member]
Net Income (Loss) Attributable to Parent, Total							$ 5,700
Long-term Line of Credit		$ 1,500			$ 1,500			$ 1,000
Subsequent Event [Member]
Proceeds from Issuance of Long-term Debt	$ 400
Cash, Cash Equivalents, and Refundable Deposits								$ 200
Long-term Debt	$ 1,900
Oxford Term Loan Agreement [Member]
Proceeds from Issuance of Long-term Debt			$ 1,500

LICENSE AND COLLABORATION AGR32

LICENSE AND COLLABORATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 09, 2015	Mar. 31, 2017	Oct. 31, 2016	Apr. 30, 2014	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description						Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.
Revenue from Contract with Customer, Including Assessed Tax					$ 76	$ 274
Amortization of Intangible Assets						$ 103	$ 103
License Agreement Option Products Description		In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
Patents [Member]
License Development and Commercialization Agreement [Line Items]
Payment for Termination				$ 2,000
Egalet
License Development and Commercialization Agreement [Line Items]
Payment for Termination				$ 2,000
Minimum Net Sales Reaching Description						one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Revenue from Contract with Customer, Including Assessed Tax	$ 5,000
Proceeds from Milestone Payment On Agreement	$ 2,500
Amortization of Intangible Assets							$ 103
Finite-Lived Intangible Asset, Useful Life				9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Year Two					$ 208	$ 208
Main Pointe Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 2,500
Licensing Agreement, Royalty Percentage		7.50%
Main Pointe Agreement [Member] | UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 1,000
Main Pointe Agreement [Member] | JAPAN
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		500
Main Pointe Agreement [Member] | South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received			$ 3,500
Kempharm Agreement [Member] | Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable			$ 1,000

REVENUE FROM CONTRACTS WITH C33

REVENUE FROM CONTRACTS WITH CUSTOMERS (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Royalty revenues	$ 76	$ 274
Egalet
Royalty revenues	70	260
MainPointe
Royalty revenues	$ 6	$ 14

REVENUE FROM CONTRACTS WITH C34

REVENUE FROM CONTRACTS WITH CUSTOMERS - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018USD ($)
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 0
Contract Balance and Performance Obligations,Description	The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2018 or December 31, 2017 was $0.00.

PROPERTY, PLANT AND EQUIPMENT35

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total	$ 2,512	$ 2,512
Less: accumulated depreciation	(1,871)	(1,833)
Net property, plant and equipment	641	679
Building and improvements
Property, Plant and Equipment [Line Items]
Total	1,273	1,273
Scientific equipment
Property, Plant and Equipment [Line Items]
Total	598	598
Computer hardware and software
Property, Plant and Equipment [Line Items]
Total	107	107
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	275	275
Land and improvements
Property, Plant and Equipment [Line Items]
Total	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Total	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Total	$ 27	$ 27

ACCRUED EXPENSES (Detail)

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities [Line Items]
Cost sharing expenses under license agreement	$ 412	$ 328
Other fees and services	34	36
Payroll, payroll taxes and benefits	77	70
Professional services	127	149
Clinical, non-clinical and regulatory services	118	326
Property taxes	13	16
Franchise taxes	14	14
Total	$ 795	$ 939

DEBT - Summary of Debt (Detail)

DEBT - Summary of Debt (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Debt Discount
Balance at Jan. 1, 2018			$ (32)
Capitalized debt discount	$ (74)	$ 0	(74)	$ 0
Amortization expense			24
Balance at Jun. 30, 2018	(82)		(82)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2018			(14)
Amortization expense			10
Balance at Jun. 30, 2018	(4)		(4)
Debt, net at Jun. 30, 2018	2,934		2,934
Loan Due January 2, 2020 [member]
Current
Balance at Jan. 1, 2018			0
Borrowings			1,500
Balance at Jun. 30, 2018	1,500		1,500
Loan Due December 1, 2018 [Member]
Current
Balance at Jan. 1, 2018			2,740
Principal payments			(1,220)
Balance at Jun. 30, 2018	1,520		1,520
Long-term [Member]
Debt Discount
Balance at Jan. 1, 2018			0
Capitalized debt discount			(74)
Amortization expense			3
Balance at Jun. 30, 2018	(71)		(71)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2018			0
Amortization expense			0
Balance at Jun. 30, 2018	0		0
Debt, net at Jun. 30, 2018	1,429		1,429
Long-term [Member] | Loan Due January 2, 2020 [member]
Current
Balance at Jan. 1, 2018			0
Borrowings			1,500
Balance at Jun. 30, 2018	1,500		1,500
Long-term [Member] | Loan Due December 1, 2018 [Member]
Current
Balance at Jan. 1, 2018			0
Principal payments			0
Balance at Jun. 30, 2018	0		0
Current [Member]
Debt Discount
Balance at Jan. 1, 2018			(32)
Capitalized debt discount			0
Amortization expense			21
Balance at Jun. 30, 2018	(11)		(11)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2018			(14)
Amortization expense			10
Balance at Jun. 30, 2018	(4)		(4)
Debt, net at Jun. 30, 2018	1,505		1,505
Current [Member] | Loan Due January 2, 2020 [member]
Current
Balance at Jan. 1, 2018			0
Borrowings			0
Balance at Jun. 30, 2018	0		0
Current [Member] | Loan Due December 1, 2018 [Member]
Current
Balance at Jan. 1, 2018			2,740
Principal payments			(1,220)
Balance at Jun. 30, 2018	$ 1,520		$ 1,520

DEBT - Interest Expense (Detail

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Schedule Of Interest Expense [Line Items]
Term loan – due December 1, 2018	$ 63	$ 133	$ 145	$ 281
Term loans – due January 2, 2020	8	0	8	0
Debt discount	13	17	24	37
Debt issue costs	4	9	10	19
Total interest expense	88	159	187	337
Less: imputed interest income on related party loan	(74)	0	(74)	0
Less: interest income	0	(1)	0	(2)
Total interest expense, net	$ 14	$ 158	$ 113	$ 335

DEBT - Additional Information (

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended			3 Months Ended		6 Months Ended
	Jul. 31, 2017	Oct. 31, 2016	Jan. 31, 2015	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2013
Debt Instrument [Line Items]
Debt instrument principal amount										$ 10,000
Debt default long term debt percentage										13.35%
Debt instrument, fee amount				$ 50		$ 50
Debt consulting placement fee						100
Debt related commitment fees and debt issuance costs				4	$ 9	10	$ 19
Debt instrument unamortized discount				$ 82		82		$ 32
Debt instrument Cash Maintenance			$ 2,500
Repayments of Debt						1,220	1,122
Debt Instrument, Periodic Payment						$ 260
Debt Instrument, Interest Rate, Effective Percentage				10.16%		10.16%
Proceeds from Issuance or Sale of Equity		$ 6,000
Interest Payable, Current				$ 767		$ 767		700
Proceeds from Issuance of Private Placement	$ 4,000
Restricted Cash and Cash Equivalents, Current				0	2,500	0	2,500		$ 2,500
Payments of Debt Issuance Costs				74	$ 0	74	0
Proceeds from Issuance of Long-term Debt						1,500	$ 0
Term Loan [Member]
Debt Instrument [Line Items]
Debt related commitment fees and debt issuance costs						231
Interest Payable, Current				767		767		$ 700
Schutte Note [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				$ 1,500		$ 1,500
Debt instrument, interest rate, stated percentage				10.16%		10.16%
Debt Instrument, Description of Variable Rate Basis						at prime plus 2.0%
Debt Instrument, Interest Rate, Stated Percentage				10.16%		10.16%
Proceeds from Issuance of Long-term Debt				$ 1,500
Debt Instrument, Maturity Date				Jan. 2, 2020
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage										8.35%
Repayments of Debt		5,000	$ 5,000
Proceeds from Issuance or Sale of Equity	2,500	2,500
Debt Instrument, Interest Rate, Stated Percentage										8.35%
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52
Proceeds from Issuance or Sale of Equity		$ 3,000
Main Pointe Agreement [Member]
Debt Instrument [Line Items]
Upfront Payments Received	2,500
Oxford Term Loan Agreement [Member]
Debt Instrument [Line Items]
Restricted Cash and Cash Equivalents, Current	$ 2,500
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount				$ 400		$ 400
Warrants to purchase common stock				60		60
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.52		$ 2.52				$ 2.52
Warrants, expiry date						December 27, 2020
Additions To Debt Instrument Unamortized Discount			$ 33
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid				$ 795		$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage						1.00%

RELATED PARTY TRANSACTIONS- Add

RELATED PARTY TRANSACTIONS- Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Jul. 31, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Related Party Transaction [Line Items]
Number of Common Stock Need to Hold to Designate As Director	600,000
Royalty Receivable			$ 94	$ 94		$ 71
Proceeds from Issuance of Long-term Debt				1,500	$ 0
Schutte Note [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Long-term Debt			1,500
Main Pointe Agreement [Member]
Related Party Transaction [Line Items]
Proceeds from License Fees Received		$ 2,500
Asset Transferred, License Agreement		$ 309
Licensing Agreement, Royalty Percentage		7.50%
Royalty Receivable			8	8
Investor [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Investor [Member] | Private Placement [Member]
Related Party Transaction [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 4,000
Sale of Stock, Number of Shares Issued in Transaction	8,912,655
Sale of Stock, Price Per Share	$ 0.4488
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Sale Of Stock Issue Price Description	85%
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 495	$ 495
Class Of Warrants Or Rights Expiry Period	5 years

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Number of Options
Number of Options Outstanding, beginning	1,842	60
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired		0
Number of Options, Modification		0
Number of Options Outstanding, ending	1,842	60
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 0.59	$ 2.52
Weighted Average Exercise Price, Issued	0	0
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Expired	0	0
Weighted Average Exercise Price, Modification	0	0
Weighted Average Exercise Price, ending	$ 0.59	$ 2.52

COMMON STOCK WARRANTS - Additio

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jul. 31, 2017	Jun. 30, 2018	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Secured Debt			$ 10,000
Stock Issued During Period, Value, New Issues	$ 4,000
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,782,531
Class of Warrant or Right, Term	5 years
Investor [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares		60,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.52	$ 2.52
Warrant | Private Placement [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 495

SHARE-BASED COMPENSATION EXPE43

SHARE-BASED COMPENSATION EXPENSE -Recognition of Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 66	$ 129	$ 142	$ 258
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	18	34	38	68
Research and Development Expense [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	11	34	24	68
Research and Development Expense [Member] | Restricted Stock units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	7	0	14	0
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	48	95	104	190
General and Administrative Expense [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	19	53	53	106
General and Administrative Expense [Member] | Restricted Stock units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 29	$ 42	$ 51	$ 84

SHARE-BASED COMPENSATION EXPE44

SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,494	1,397
Number of Options, Granted	0	0
Number of Options, Exercised	0	(1)
Number of Options, Forfeited or expired	(145)	0
Number of Options Outstanding, ending	1,349	1,396
Number of Options exercisable	1,129	1,190
Weighted Average Exercise Price, beginning	$ 12.33	$ 13.57
Weighted Average Exercise Price, Granted	0	0
Weighted Average Exercise Price, Exercised	0	(0.92)
Weighted Average Exercise Price, Forfeited or expired	(46.39)	0
Weighted Average Exercise Price, ending	8.68	13.58
Weighted Average Exercise Price, Options exercisable	$ 10.26	$ 15.71

SHARE-BASED COMPENSATION EXPE45

SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Detail) - Non Vested Stock Options [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning | shares	270
Granted | shares	0
Vested | shares	(46)
Forfeited | shares	(4)
Outstanding, ending | shares	220
Outstanding beginning, Weighted Average Fair Value | $ / shares	$ 0.46
Granted, Weighted Average Fair Value | $ / shares	0
Vested, Weighted Average Fair Value | $ / shares	0.77
Forfeited, Weighted Average Fair Value | $ / shares	0.41
Outstanding ending, Weighted Average Fair Value | $ / shares	$ 0.39

SHARE-BASED COMPENSATION EXPE46

SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	462	91
Granted	267	238
Distributed	(262)	(67)
Vested	0	0
Forfeited or expired	(8)	0
Outstanding, ending	459	262
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	262	91
Granted	0	0
Distributed	(262)	(67)
Vested	133	118
Forfeited or expired	0	0
Outstanding, ending	133	142

SHARE-BASED COMPENSATION EXPE47

SHARE-BASED COMPENSATION EXPENSE- Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended				3 Months Ended		6 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	May 31, 2014	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Nov. 30, 2017
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested					$ 0	$ 0	$ 0	$ 0
Unrecognized compensation cost on unvested option awards outstanding					34		34
Allocated Share-based Compensation Expense					66	129	$ 142	258
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							5 months
Restricted Stock Units (RSUs) [Member]
Employee Benefit Plans Disclosure [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options					27		$ 27
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							6 months
Restricted Stock Units (RSUs) [Member] | January 4, 2016 Award Distributed [Member]
Employee Benefit Plans Disclosure [Line Items]
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution				1
Restricted Stock Units (RSUs) [Member] | Director [Member]
Employee Benefit Plans Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 41			19		$ 19
Restricted Stock Units (RSUs) [Member] | Director [Member] | General and Administrative Expense [Member]
Employee Benefit Plans Disclosure [Line Items]
Allocated Share-based Compensation Expense					$ 7	$ 13	$ 20	$ 25
Restricted Stock Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,000		1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			60
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%	100.00%	25.00%
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings	262
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									1,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	67	200
Restricted Stock Award Plan [Member] | Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			18
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings	24
Restricted Stock Award Plan [Member] | Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			67
Restricted Stock Award Plan [Member] | January 4, 2016 Award Distributed [Member]
Employee Benefit Plans Disclosure [Line Items]
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution			66
Restricted Stock Award Plan [Member] | Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			49
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings	238
Restricted Stock Award Plan [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			22
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 41
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				400
Share-based Compensation Arrangement by Share-based Payment Award, Description			stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award							3
Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Description	stock, for up to 40%

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Federal NOLs	$ 169,000		$ 168,000
U.S. statutory tax rate	35.00%
State income tax benefits			$ 1,000
Operating Loss Carryforwards Expiration Term			20 years
Operating Loss Carry Forwards Expiration Year			2,037
Tax Credit Carryforward, Amount			$ 150
Scenario, Plan [Member]
Income Tax Disclosure [Line Items]
U.S. statutory tax rate		21.00%

NET LOSS PER SHARE - Reconcilia

NET LOSS PER SHARE - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
EPS – basic and diluted
Numerator: net loss	$ (1,261)	$ (2,149)	$ (2,755)	$ (1,744)
Denominator (weighted):
Common shares	21,034	11,883	21,034	11,884
Vested RSUs	67	83	34	54
Basic and diluted weighted average shares outstanding	21,101	11,966	21,068	11,938
EPS – basic and diluted	$ (0.06)	$ (0.18)	$ (0.13)	$ (0.15)
Common shares issuable:
Total excluded common shares	3,517	1,576	3,517	1,576
Employee Stock Option [Member]
Common shares issuable:
Total excluded common shares	1,349	1,396	1,349	1,396
Warrant [Member]
Common shares issuable:
Total excluded common shares	1,842	60	1,842	60
Restricted Stock Units (RSUs) [Member]
Common shares issuable:
Total excluded common shares	326	120	326	120

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 12, 2018	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2018
Commitments and Contingencies Disclosure [Line Items]
Accrued Cost Sharing Expenses Clinical Studies				$ 412
Gain Contingency, Unrecorded Amount	$ 10,000
Loss Contingency, Damages Sought, Value	$ 10,000
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense		$ 250	$ 500

SUBSEQUENT EVENT - Additional I

SUBSEQUENT EVENT - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 02, 2018	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt			$ 1,500	$ 0
Debt Instrument, Basis Spread on Variable Rate	2.00%
Long-term Debt		$ 2,934	2,934
Palatine Illinois [Member]
Subsequent Event [Line Items]
Operating Leases, Rent Expense, Net			$ 2
Schutte Note [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt		$ 1,500
Debt Instrument, Maturity Date		Jan. 2, 2020
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt	$ 400
Long-term Debt	1,900
Subsequent Event [Member] | Loan Agreement With Oxford [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt	400
Long-term Debt	$ 1,900
Subsequent Event [Member] | Schutte Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date	Jan. 2, 2020